via
A: Viacom Inc., symbols VIA, $40.75 (class A: one vote per share) and VIAB $36.14 (class B: non-voting) on Nasdaq (Shares outstanding: 396.7 million; Market cap: $14.5 billion; www.viacom.com) is a leading producer and distributor of movies, television programs and other entertainment content....
Using bonds for retirement income has often been standard investing advice for the last 50 years—but we think it’s bad advice.
Growth investing isn’t such a gamble if you follow these three tips.
EXTENDICARE INC., $8.69, symbol EXE on Toronto, owns 64 senior-care facilities that can house 8,464 residents—both long- and short-term. It manages another 54 residences that are home to 6,426 seniors. Extendicare also operates 47 ParaMed Home Health Care branches in six provinces. ParaMed’s 10,900 staff members provide nursing care and other forms of assistance to clients who remain in their own homes. In the three months ended March 31, 2016, the company’s revenue rose 29.8%, to $284.4 million from $202.2 million a year earlier. Cash flow jumped 72.5%, to $12.2 million, or $0.14 a share, from $7.1 million, or $0.08....
One of our most asked questions is if we prefer stocks or bonds for most portfolios—and the short answer is stocks.
The history of ETFs is one of the evolution of indexing and of market innovation.
Over-the-counter trading is for investors who don’t mind risk and are willing to chance losing their money
First Solar Inc., $48.01, symbol FSLR on Nasdaq (Shares outstanding: 100.9 million; Market cap: $5.0 billion; www.firstsolar.com), designs and manufactures modules for converting solar energy into electricity. The company makes its modules using a proprietary thin-film semiconductor technology it believes has a lower manufacturing cost per watt than traditional crystalline silicon modules. First Solar first sold shares to the public for $20 each in November 2006. Unlike many solar companies, First Solar is profitable, with forecast earnings of $3 a share this year. The stock trades at 16.0 times that estimate. The company’s balance sheet is also strong, with cash of $1.8 billion, or $17.86 a share, and just $257.8 million of long-term debt....
Pat McKeough responds to many requests from members of his Inner Circle for specific stock tips, as well as questions on investment strategy and the economy. Every week, his comments and recommendations on the most intriguing questions of the past week go out to all Inner Circle members. And each week we offer you a report on one of the stocks profiled in these Q&A sessions. We give you Pat’s buy-hold-sell recommendation as well as his analysis of the stock. This is part of the specific buy, hold and sell advice we offer you in our daily posts. Every week you get “A Stock to Sell” on Monday, “Best Canadian Stocks” on Tuesday, and “Our Top U.S. Stocks” on Thursday. This week an Inner Circle member asked us about a company that is in the forefront of treating heart disease. Edwards Lifesciences makes the bulk of its money from heart valve technology and the rest on critical care, or hemodynamic monitoring. Pat examines Edwards’ leading products and particularly the surge in revenue from the Transcatheter Heart Valve. He also considers whether the company’s shares can continue their rise. Q: Good day, Pat: Can you please provide your opinion on Edwards Lifesciences? Thanks....
Edwards Lifesciences, $101.39, symbol EW on New York (Shares outstanding: 106.0 million; Market cap: $10.8 billion; www.edwards.com), develops technologies for treating heart disease and monitoring critically ill patients’ cardiovascular systems. The company operates in three segments:
- Surgical Heart Valve Therapy (42% of revenue): Edwards makes a range of heart valves and other products that are used to replace or repair a patient’s diseased or defective heart valves. These products include pericardial valves from biologically inert animal tissue sewn onto wireform stents.
- Transcatheter Heart Valves (29% of sales): Transcatheter valve technology offers a less invasive means of treating heart valve disease. It’s designed to let physicians deliver replacement valves via a catheter through the body’s cardiovascular system, eliminating the need to open the chest.
- Critical Care (29% of sales): This division’s products focus on hemodynamic monitoring, which aims to assess a critically ill patient’s cardiovascular system and its response to tissue oxygen demands. Hemodynamic monitoring measures the blood pressure inside the veins, heart and arteries. It also measures the blood’s flow and oxygen content.